DE69218813T2 - Ringsubstituierte 2-Amino-1,2,3,4-tetrahydronaphthaline - Google Patents

Ringsubstituierte 2-Amino-1,2,3,4-tetrahydronaphthaline

Info

Publication number
DE69218813T2
DE69218813T2 DE69218813T DE69218813T DE69218813T2 DE 69218813 T2 DE69218813 T2 DE 69218813T2 DE 69218813 T DE69218813 T DE 69218813T DE 69218813 T DE69218813 T DE 69218813T DE 69218813 T2 DE69218813 T2 DE 69218813T2
Authority
DE
Germany
Prior art keywords
alkyl
tetrahydronaphthalenes
amino
substituted
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69218813T
Other languages
English (en)
Other versions
DE69218813D1 (de
Inventor
Craig Steven Hoechstetter
Diane Lynn Huser
John Mehnert Schaus
Robert Daniel Titus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69218813D1 publication Critical patent/DE69218813D1/de
Application granted granted Critical
Publication of DE69218813T2 publication Critical patent/DE69218813T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials
DE69218813T 1991-02-08 1992-02-03 Ringsubstituierte 2-Amino-1,2,3,4-tetrahydronaphthaline Expired - Fee Related DE69218813T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65358391A 1991-02-08 1991-02-08

Publications (2)

Publication Number Publication Date
DE69218813D1 DE69218813D1 (de) 1997-05-15
DE69218813T2 true DE69218813T2 (de) 1997-08-14

Family

ID=24621480

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69218813T Expired - Fee Related DE69218813T2 (de) 1991-02-08 1992-02-03 Ringsubstituierte 2-Amino-1,2,3,4-tetrahydronaphthaline
DE69231538T Expired - Fee Related DE69231538T2 (de) 1991-02-08 1992-02-03 Ringsubstituierte 2-Amino-1,2,3,4-tetrahydronaphtahline und 3-Aminochromane

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69231538T Expired - Fee Related DE69231538T2 (de) 1991-02-08 1992-02-03 Ringsubstituierte 2-Amino-1,2,3,4-tetrahydronaphtahline und 3-Aminochromane

Country Status (26)

Country Link
US (2) US5426226A (de)
EP (2) EP0498590B1 (de)
JP (1) JP3283892B2 (de)
KR (1) KR100219995B1 (de)
CN (2) CN1036392C (de)
AT (2) ATE197145T1 (de)
AU (2) AU653197B2 (de)
BR (1) BR9200426A (de)
CA (1) CA2060815C (de)
CZ (1) CZ288067B6 (de)
DE (2) DE69218813T2 (de)
DK (2) DK0712837T3 (de)
ES (2) ES2102456T3 (de)
FI (1) FI920526A (de)
GR (2) GR3023601T3 (de)
HU (3) HU221184B1 (de)
IE (1) IE920417A1 (de)
IL (3) IL114760A (de)
MX (1) MX9200505A (de)
MY (1) MY116454A (de)
NO (1) NO301825B1 (de)
NZ (2) NZ241495A (de)
PT (1) PT712837E (de)
RU (2) RU2057751C1 (de)
YU (1) YU48927B (de)
ZA (1) ZA92767B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2048846A1 (en) * 1990-08-15 1992-02-16 Craig Steven Hoechstetter Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes, 3-aminochromanes, and aminothiochromanes
ATE197145T1 (de) * 1991-02-08 2000-11-15 Lilly Co Eli Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
EP0697894A4 (de) * 1993-03-31 1996-05-01 Univ Pennsylvania Dopamin d-3 und serotonin (5-ht 1a) rezeptor-liganden und bildgebunde mittel
IL110857A0 (en) * 1993-09-09 1994-11-28 Lilly Co Eli Cessation of tobacco use
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
US6355674B1 (en) 1997-04-30 2002-03-12 Eli Lilly And Company Aminotetralins as 5-HT1D α Agonists
EP1052982A4 (de) * 1997-04-30 2004-10-06 Lilly Co Eli AMINOTETRALINE ALS 5HT1D-alpha AGONISTEN
NZ501251A (en) 1997-07-01 2001-09-28 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
BR9913503A (pt) 1998-09-09 2002-01-29 Ishihara Sangyo Kaisha Derivados de benzeno-fundidos úteis como herbicidas
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
US6792563B1 (en) * 2000-04-28 2004-09-14 Intel Corporation Method and apparatus for bus activity tracking
CA2472763A1 (en) * 2002-02-13 2003-08-21 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192641A (en) * 1979-01-26 1984-10-19 Hoffmann La Roche Substituted acetophenones and pharmaceutical compositions
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
CA1335591C (en) * 1988-05-23 1995-05-16 James Arthur Nixon Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
FR2647365B1 (fr) * 1989-05-24 1991-08-30 Inst Francais Du Petrole Catalyseur multifonctionnel pour le traitement des gaz d'echappement des moteurs a combustion interne, contenant de l'uranium, au moins un promoteur de l'uranium et au moins un metal precieux et sa preparation
SE8901889D0 (sv) * 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
ATE172712T1 (de) * 1989-05-31 1998-11-15 Upjohn Co Zns-wirksame 8-heterocyclyl-2-aminotetralin derivate
DE3919624A1 (de) * 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA2028341A1 (en) * 1989-10-23 1991-04-24 Junichi Sato 5-substituted-2,4-diphenylpyrimidine derivatives, their production and use
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
CA2048846A1 (en) * 1990-08-15 1992-02-16 Craig Steven Hoechstetter Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes, 3-aminochromanes, and aminothiochromanes
ATE197145T1 (de) * 1991-02-08 2000-11-15 Lilly Co Eli Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane

Also Published As

Publication number Publication date
CN1140167A (zh) 1997-01-15
NO920489L (no) 1992-08-10
US5571942A (en) 1996-11-05
CN1036392C (zh) 1997-11-12
AU653197B2 (en) 1994-09-22
JP3283892B2 (ja) 2002-05-20
EP0712837B1 (de) 2000-10-25
IE920417A1 (en) 1992-08-12
CN1052218C (zh) 2000-05-10
MX9200505A (es) 1992-08-01
CA2060815A1 (en) 1992-08-09
HU225163B1 (en) 2006-07-28
HU211848A9 (en) 1995-12-28
GR3023601T3 (en) 1997-08-29
RU2057751C1 (ru) 1996-04-10
FI920526A (fi) 1992-08-09
CZ288067B6 (cs) 2001-04-11
EP0712837A3 (de) 1997-05-21
HUT72659A (en) 1996-05-28
HU9500495D0 (en) 1995-04-28
CZ33292A3 (en) 1993-03-17
RU94044322A (ru) 1996-10-10
IL114760A0 (en) 1995-11-27
HUT62569A (en) 1993-05-28
AU8168794A (en) 1995-02-23
KR100219995B1 (ko) 1999-09-01
NO920489D0 (no) 1992-02-06
ES2102456T3 (es) 1997-08-01
GR3035190T3 (en) 2001-04-30
IE970857A1 (en) 2000-02-23
ATE197145T1 (de) 2000-11-15
NO301825B1 (no) 1997-12-15
PT712837E (pt) 2001-03-30
ZA92767B (en) 1993-08-03
YU48927B (sh) 2002-12-10
IL100858A (en) 1996-03-31
DK0498590T3 (da) 1997-05-05
DE69218813D1 (de) 1997-05-15
YU12992A (sh) 1995-01-31
EP0498590B1 (de) 1997-04-09
AU1077592A (en) 1992-08-13
US5426226A (en) 1995-06-20
DK0712837T3 (da) 2000-11-20
RU2105756C1 (ru) 1998-02-27
DE69231538T2 (de) 2001-06-07
IL114760A (en) 1997-11-20
DE69231538D1 (de) 2000-11-30
CN1063870A (zh) 1992-08-26
BR9200426A (pt) 1992-10-13
EP0712837A2 (de) 1996-05-22
ES2153071T3 (es) 2001-02-16
AU664520B2 (en) 1995-11-16
HU9200396D0 (en) 1992-04-28
CA2060815C (en) 2002-05-14
IL100858A0 (en) 1992-11-15
NZ241495A (en) 1994-10-26
ATE151419T1 (de) 1997-04-15
KR920016454A (ko) 1992-09-24
NZ264302A (en) 1995-04-27
EP0498590A1 (de) 1992-08-12
FI920526A0 (fi) 1992-02-07
HU221184B1 (en) 2002-08-28
JPH04327579A (ja) 1992-11-17
MY116454A (en) 2004-02-28

Similar Documents

Publication Publication Date Title
DE69218813T2 (de) Ringsubstituierte 2-Amino-1,2,3,4-tetrahydronaphthaline
ZA881377B (en) Process for improving the photochemical stability of dyeings on polyester fibre materials
AU639053B2 (en) Immunosuppressant and process for preparing the same
IT1250749B (it) Composti eterociclici ad attivita' a ii antagonista
HU9202199D0 (en) A new medical preparative containing benzomorphane
HUP9700103A2 (hu) 1,3,4-Tiadiazol-származékok és eljárás előállításukra

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee